Genetically detoxified pertussis toxin induces superior antigen specific CD4 T cell responses compared to chemically detoxified pertussis toxin
- 19 March 2019
- journal article
- research article
- Published by Taylor & Francis in Human Vaccines & Immunotherapeutics
- Vol. 15 (5) , 1167-1170
Abstract
Pertussis is resurgent worldwide. Currently available acellular pertussis vaccines contain chemically detoxified pertussis toxin (PTc); a highly immunogenic genetically detoxified pertussis toxin (PTg) vaccine has been off the market for over a decade. We compared CD4+ T cell and B cell responses induced by genetically detoxified pertussis toxin (PTg) and chemically detoxified pertussis toxin (PTc) using naive human neonatal cells. Responses to novel adjuvants were also assessed. PTg induced significant antigen-specific CD4+ T cell activation and IL17 secretion than PTc. TLR agonist combinations improved PTg induced T cell-CD69 expression and IL17 secretion.Keywords
Funding Information
- National Institutes of Health/National Institute of Allergy and Infectious Diseases (R03AI117700)
- National Institute of Allergy and Infectious Diseases (R03AI117700)
This publication has 16 references indexed in Scilit:
- TLR agonist combinations that stimulate Th type I polarizing responses from human neonatesInnate Immunity, 2018
- Addition of a TLR7 agonist to an acellular pertussis vaccine enhances Th1 and Th17 responses and protective immunity in a mouse modelVaccine, 2017
- The Pertussis ProblemClinical Infectious Diseases, 2013
- Acellular pertussis vaccines protect against disease but fail to prevent infection and transmission in a nonhuman primate modelProceedings of the National Academy of Sciences, 2013
- Acellular Pertussis Vaccine at Birth and One Month Induces Antibody Responses By Two Months of AgeThe Pediatric Infectious Disease Journal, 2010
- Combined Tetanus, Diphtheria, and 5-Component Pertussis Vaccine for Use in Adolescents and AdultsJAMA, 2005
- Immunogenicity of a Three-Component Acellular Pertussis Vaccine Administered at BirthPediatrics, 2003
- Quantitative Expression of Toll-Like Receptor 1–10 mRNA in Cellular Subsets of Human Peripheral Blood Mononuclear Cells and Sensitivity to CpG OligodeoxynucleotidesThe Journal of Immunology, 2002
- Safety and Immunogenicity of Six Acellular Pertussis Vaccines and One Whole-Cell Pertussis Vaccine Given as a Fifth Dose in Four- to Six-Year-Old ChildrenPediatrics, 2000
- A Safety and Immunogenicity Comparison of 12 Acellular Pertussis Vaccines and One Whole-Cell Pertussis Vaccine Given as a Fourth Dose in 15- to 20-Month-Old ChildrenPediatrics, 1997